Adma Biologics earnings were $182.4M for the trailing 12 months ending Sep 30, 2026, with -10.2% growth year over year. The latest ADMA earnings report on Sep 30, 2026 announced Q3 2026 earnings of $49.9M, up 31.9% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, ADMA reported annual earnings of $146.9M, with -25.7% growth.
ADMA past earnings growth
How has ADMA's earnings growth performed historically?
On ADMA's earnings call on Nov 4, 2026, Adma Biologics (NASDAQ: ADMA) reported Q3 2026 earnings per share (EPS) of $0.22, up 46.67% year over year. Total ADMA earnings for the quarter were $49.88 million. In the same quarter last year, Adma Biologics's earnings per share (EPS) was $0.15.
As of the last Adma Biologics earnings report, Adma Biologics is currently profitable. Adma Biologics's net profit (also called net income) for the twelve months ending Sep 30, 2026 was $182.41 million, a 12.91% decrease year over year.
What was ADMA's earnings growth in the past year?
As of Adma Biologics's earnings date in Nov 4, 2026, Adma Biologics's earnings has grown -10.23% year over year. This is 81.62 percentage points lower than the US Biotechnology industry earnings growth rate of 71.39%. ADMA earnings in the past year totalled $182.41 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.